Repeated cycles of peptide receptor radionuclide therapy (PRRT) - Side-effects and response to the radioisotope 90Y-DOTA-TATE or 90Y/177Lu DOTA-TATE therapy in patients with disseminated NET

被引：0
|
作者：
Sowa-Staszczak, Anna [1 ]
Kunikowska, Jolanta [2 ]
Krolicki, Leszek [2 ]
Mikolajczak, Renata [3 ]
Pawlak, Dariusz [3 ]
Stefanska, Agnieszka [1 ]
Tomaszuk, Monika [1 ]
Trofimiuk, Malgorzata [1 ]
Pach, Dorota [1 ]
Hubalewska-Dydejczyk, Alicja [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Dept Endocrinol, Nucl Med Unit, Krakow, Poland
[2] Warsaw Med Univ, Dept Nucl Med, Warsaw, Poland
[3] IAE Radioisotope Ctr POLATOM, Res & Dev, Otwock, Poland
来源：
JOURNAL OF NUCLEAR MEDICINE | 2011年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
300
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Results of 90Y-DOTA TATE and 90Y/177LuDOTATATE therapy in patients with neuroendocrine tumors - own experience
    Kunikowska, J.
    Krolicki, L.
    Mikolajczak, R.
    Pawlak, D.
    Hubalewska-Dydejczyk, A.
    Sowa-Staszczak, A.
    Pacho, R.
    Kazbieruk, M.
    Kobylecka, M.
    Maczewska, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S349 - S349
  • [32] Radioligand Therapy with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Dmochowska, Beata
    Mroz, Adrianna
    Zmudzki, Wawrzyniec
    Kaminski, Grzegorz
    PHARMACEUTICALS, 2023, 16 (09)
  • [33] Initial study to AssessTumor response on 90Y-DOTA-TATE radionuclide treatment in patients with extensive GEP-NET
    Cwikla, JB
    Nasierowska-Guttmejer, A
    Seklecka, N
    Jeziorski, KG
    Bator, A
    Walecki, J
    NEUROENDOCRINOLOGY, 2006, 83 (01) : 32 - 32
  • [34] The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET
    Zemczak, Anna
    Gut, Pawel
    Pawlak, Dariusz
    Kolodziej, Maciej
    Krolicki, Leszek
    Kos-Kudla, Beata
    Ruchala, Marek
    Kaminski, Grzegorz
    Kunikowska, Jolanta
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2021, 2021
  • [35] Overall survival (OS) and progression-free survival (PFS) in patients with advanced, non-resectable, progressive rectal NET treated with 90Y DOTA-TATE, 177Lu DOTA-TATE and mix of both as systemic radioligand therapy: Real-world data
    Cwikla, J. B.
    Kolasinska-Cwikla, A. D.
    Sankowski, A.
    Palucki, J.
    Roszkowska-Purska, K.
    Chrapowicki, E.
    Ostrowski, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S760 - S760
  • [36] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET)
    Mc Ewan, A.
    Wieler, M.
    Makis, W.
    McMullen, T.
    Morrish, D.
    MacLeod, S.
    Schrader, L.
    Sawyer, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 94 - 94
  • [37] Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE in the treatment of malignant insulinoma: a case report of remarkable clinical and imaging response
    Barbosa, D.
    Duarte, H.
    Paula Santos, A.
    Ferro, J.
    Prospero, I.
    Silva, D.
    Gil-Santos, S.
    Calheiros, R.
    Fontao de Castro, S.
    Ferreira, G.
    Teixeira, P.
    Lucena Sampaio, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S219 - S219
  • [38] Optimized Combination Therapy Applied to 90Y and 177Lu Peptide Receptor Radionuclide Therapy (PRRT) Based on Tumor Size Distribution
    Hobbs, R. F.
    Sgouros, G.
    Frey, E. C.
    Wahl, R. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S306 - S306
  • [39] Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment
    Ataei-Nakhaei, Saeideh
    Aryana, Kamran
    Mostafavi, Sayyed Mostafa
    Kosari, Hadis Mohammadzadeh
    Esmatinia, Mohammad
    Aghaee, Atena
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (02):
  • [40] 90Y and 177LU labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy
    Liu, S
    Cheung, E
    Ziegler, MC
    Rajopadhye, M
    Edwards, DS
    BIOCONJUGATE CHEMISTRY, 2001, 12 (04) : 559 - 568
12345